Previous Close | 0.0108 |
Open | 0.0108 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0108 - 0.0108 |
52 Week Range | 0.0108 - 1.8600 |
Volume | |
Avg. Volume | 20 |
Market Cap | 317.179M |
Beta (5Y Monthly) | 0.56 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2200 |
Earnings Date | Mar 28, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that, VenusP-Valve, the company's in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, cleared approval from Health Canada.
Venus Medtech is changing how the world treats structural heart disease. The company will present its products at its booth (#28), during two symposia, in multiple podium presentations and at a special cocktail reception where it will officially launch the SMART-ALIGN multicenter clinical study.